Senator Unleashes New Anti-Abortion Strategy

March 17, 2026

Ultrasound images and a bottle of misoprostol next to a pregnancy test

Sen. Josh Hawley just aimed straight at the Biden-era mail-order abortion-pill pipeline by pushing a bill that would yank FDA approval for mifepristone nationwide.

Quick Take

Sen. Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act on March 11, 2026, seeking to revoke FDA approval for mifepristone.
The proposal would effectively ban the most common abortion method in the U.S., as medication abortion accounted for 63% of abortions in 2023.
The bill includes a provision allowing women to sue mifepristone manufacturers for damages, creating new legal exposure for the industry.
The fight lands in a post-Dobbs landscape where states regulate abortion, but federal agencies expanded access through mail-order policies under Biden.
Political reality remains uncertain: President Trump previously said he would veto a national abortion ban, and Congress has struggled to advance sweeping abortion legislation.

What Hawley’s bill would do—and why it’s designed to bypass the usual state-by-state fight

Sen. Hawley (R-Mo.) announced his bill March 11, 2026, arguing Congress should step in to revoke the FDA approval granted to mifepristone in 2000. The measure targets the drug’s federal regulatory status rather than attempting to police individual state abortion laws—an approach that could reshape access across the country if enacted. Hawley framed the move as a health-and-safety question and criticized corporate profit motives tied to the drug’s use.

A companion bill was introduced in the House by Rep. Diana Harshbarger (R-Tenn.), signaling that leadership on the issue is trying to move in both chambers at once. Hawley staged a Capitol press conference with women who said they experienced complications after taking mifepristone, positioning their stories as a rebuttal to the idea that remote prescribing is “routine” medicine. The legislation’s core claim is simple: the FDA approval itself should be pulled.

The post-Biden policy backdrop: mail-order abortion pills and the federal agency question

After the Supreme Court’s 2022 Dobbs decision returned abortion regulation to the states, the practical battleground shifted toward federal agencies and distribution rules—especially for medication abortion. Under the Biden administration, the FDA’s policies allowed broader access including mail-order dispensing, which critics said undercut state-level restrictions by making pills easier to obtain without in-person medical oversight. Hawley’s approach leans into that fault line by seeking a federal clampdown where states cannot fully control cross-border shipping.

The Supreme Court’s 2024 decision in the mifepristone dispute is another key reason this is back in Congress. The justices unanimously rejected a challenge seeking to reverse FDA approval and expanded access, but they did so on standing grounds—meaning the Court did not rule on the underlying safety arguments. That leaves elected branches—and the FDA itself—still exposed to pressure over whether the agency’s prior decisions should be revisited, tightened, or reversed entirely.

Safety claims, disputed data, and what can—and can’t—be verified from the public record

Hawley and allied pro-life groups cite research from the Ethics and Public Policy Center asserting that complications are far higher than the FDA label suggests, including a widely repeated claim of a multiple-fold increase. Supporters argue the risk grows when pills are prescribed through telehealth and delivered by mail, because complications may unfold away from immediate medical care.

That evidentiary gap matters because Congress is being asked to override a long-standing FDA approval. Hawley’s bill builds its public case around the idea that “the science is clear,” but also shows the dispute is not settled in the broader medical and political ecosystem. The FDA has pledged a safety review, and Commissioner Marty Makary has referenced reviewing “the totality of the data,” yet no clear timeline or methodology is publicly confirmed in these sources.

The legal lever inside the bill: letting women sue manufacturers

One of the most consequential policy elements is the proposed private right of action allowing women to sue mifepristone manufacturers for damages. In practical terms, that would change the risk calculation for companies tied to the drug, including the primary manufacturer, Danco Laboratories. For conservatives wary of corporate capture and administrative-state decisions that feel insulated from accountability, this provision functions as a liability backstop. Hawley has emphasized both safety concerns and corporate profit in his messaging.

At the same time, the bill’s political path is unclear. Broad abortion restrictions have repeatedly stalled in Congress after Dobbs, and President Trump’s past campaign-position signals—opposition to a national abortion ban and willingness to veto one—add uncertainty about how far the White House would go. That sets up a familiar tension: pro-life lawmakers want federal action, while executive and congressional math may push narrower, incremental steps instead.

Josh Hawley has introduced a bill to ban abortion pills, drawing on dubious data to justify Congress revoking the FDA's approval of these drugs https://t.co/1fEzJK9b3S

— reason (@reason) March 16, 2026

For voters who watched the Biden years normalize sweeping executive-agency moves on high-stakes cultural issues, this episode is also a reminder of how much power lives inside federal regulators. Hawley’s proposal is an attempt to drag that power back into the open—into Congress—where accountability is clearer, even if the outcome is uncertain. Limited public information about the FDA’s pending review means the next turning point may come from either legislative momentum or whatever the agency ultimately releases.